# US 2024/0197733 A1 · A gaba receptor modulator for use in the treatment of pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197733 A1
- Document ID: US20240197733A1
- Status: Published application
- Kind: A1
- Application number: 18/554,824
- Filed: 2022-04-13
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: Saniona A/S
- Applicants: Saniona A/S
- Inventors: Karin Sandager NIELSEN; Dipak AMRUTKAR; Dean CARSON
- Web page: https://patentgrep.com/patent/US20240197733A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 25/02: for peripheral neuropathies
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol or a pharmaceutically acceptable salt thereof, which is a known GABA receptor modulator, for the treatment of disorders characterized by severe pain, such as trigeminal neuralgia and postoperative pain.

## Claims

### Claim 1

A compound for use in the treatment of facial pain in a subject, wherein the compound is 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound for use according to claim 1, wherein the facial pain is orofacial pain and/or craniofacial pain.

### Claim 3

The compound for use according to any one of the preceding claims, wherein the facial pain is trigeminal neuralgia (TN).

### Claim 4 (depends on 1, 2)

The compound for use according to any one of claims 1 to 2, wherein the facial pain is associated with migraine or headache.

### Claim 5 (depends on 1, 2)

The compound for use according to any one claims 1 to 2, wherein the pain is associated with atypical facial pain or mononeuropathies.

### Claim 6

The compound for use according to any one of the preceding claims, wherein the subject is administered a dose in the range of 0.001-100 mg/kg perorally.

### Claim 7

A compound for use in the treatment of postoperative pain in a subject, wherein the compound is 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The compound for use according to claim 7, wherein the postoperative pain is acute postoperative pain.

### Claim 9 (depends on 7)

The compound for use according to claim 7, wherein the postoperative pain is chronic postoperative pain.

### Claim 10 (depends on 7)

The compound for use according to claim 7, wherein the pain is chronic pain after surgery, such as after surgical procedures comprising spinal surgery, herniotomy, hysterectomy, amputation, thoracotomy, breast surgery, and arthroplasty.

### Claim 11 (depends on 7, 8, 9, 10)

The compound for use according to any one of claims 7 to 10, wherein the treatment of the subject is initiated more than 2 days prior to the subject undergoing surgery.

### Claim 12 (depends on 7, 8, 9, 10, 11)

The compound for use according to any one of claims 7 to 11, wherein the treatment is initiated more than 2 days, such as 3, such as 4, such as 5, such as 6, such as 7, such as 10, such as 20, such as 30 days prior to the subject undergoing surgery.

### Claim 13 (depends on 7, 8, 9, 10, 11, 12)

The compound for use according to any one of claims 7 to 12, wherein the subject is administered a dose in the range of 0.001-100 mg/kg perorally.

### Claim 14

A method for treatment of facial pain and/or postoperative pain comprising administration of 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim 15

Use of 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of facial pain and/or postoperative pain.